MAM
TTNP

Meeder Asset Management’s Titan Pharmaceuticals TTNP Stock Holding History

Meeder Asset Management’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1
Closed – – 1808
2018
Q3 		$0 Hold
1
– – ﹤0.01% 1693
2018
Q2 		$5.47K Hold
1
– – ﹤0.01% 1258
2018
Q1 		$3K Hold
1
– – ﹤0.01% 1334
2017
Q4 		$4K Hold
1
– – ﹤0.01% 1384
2017
Q3 		$4K Hold
1
– – ﹤0.01% 1337
2017
Q2 		$4K Hold
1
– – ﹤0.01% 1274
2017
Q1 		$7K Buy
+1
New +$14.1K ﹤0.01% 965
2016
Q4 		– Hold
0
– – – 909

Other funds holding TTNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
WPA
Winning Points Advisors Boca Raton, Florida $74.8M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Meeder Asset Management's TTNP Position: Q4 2018 in Review

Meeder Asset Management sold out of Titan Pharmaceuticals (TTNP) in Q4 2018, closing a stake of 1 share.

Meeder Asset Management first reported a position in TTNP in Q1 2017 and held it in 7 quarters. The position peaked at $7K in Q1 2017. 26 funds tracked by Wall St. Rank hold TTNP as of Q4 2018.

  • Meeder Asset Management reported no remaining Titan Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Meeder Asset Management sold 1 Titan Pharmaceuticals share in Q4 2018.
  • Meeder Asset Management first reported a position in Titan Pharmaceuticals in Q1 2017 and held it in 7 quarters.
  • Meeder Asset Management's Titan Pharmaceuticals position peaked at $7K in Q1 2017.
  • 26 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q4 2018.

Based on Meeder Asset Management's 13F filing for Q4 2018, filed 17 Jan 2019.